CRDL | Cardiol Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.1219 - 2.2800
52 Week Range	0.6610 - 3.12
Beta	0.86
Implied Volatility	228.93%
IV Rank	7.97%
Day's Volume	288,468
Average Volume	327,201
Shares Outstanding	69,881,700
Market Cap	153,739,740
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2019-01-15

Valuation
Profitability
Growth
Health
P/E Ratio	-6.87
Forward P/E Ratio	N/A
EPS	-0.32
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	22
Country	Canada
Website	CRDL

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

CRDL's peers: FLGC, ABVC, INDP, HCWB, PRFX

*Chart delayed

Analyzing fundamentals for CRDL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see CRDL Fundamentals page.

Watching at CRDL technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CRDL Technicals page.